Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04090645 · ClinicalTrials.gov registry record · NA
TheraSphere & Treatment of Unresectable Primary or Unresectable Secondary Liver Cancer
A NA study of Liver, Cancer of, Non-Resectable, sponsored by Methodist Health System.
- Completed
- Registry status
- NA
- Development phase
- 187
- Enrollment target
- 1
- Study location
NCT04090645: Completed NA study of Liver, Cancer of, Non-Resectable, sponsored by Methodist Health System.
NCT04090645 is a NA study of Liver, Cancer of, Non-Resectable that has completed, run by Methodist Health System. The registered enrollment target is 187 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04090645, a NA study of Liver, Cancer of, Non-Resectable, has completed, sponsored by Methodist Health System.
- COMPLETED
- Registry status
- NA
- Development phase
- 187 participants
- Enrollment target
- 1
- Study location
Study Summary
Protocol Synopsis Title A Humanitarian Device Exemption Use Protocol of TheraSphere® For Treatment of Unresectable Primary or Secondary Liver Neoplasia Supplier BTG International Canada Inc. Type of Clinical Use Post-Marketing: TheraSphere® commercially distributed under HDE # 980006 Objectives • Provide supervised access to TheraSphere® therapy at this institution * Evaluate response to treatment * Evaluate toxicities and adverse experiences associated with TheraSphere® treatment * Evaluate survival time Number of Patients Up to 100 patients per year, expandable following completion of the first cohort. Patients will be excluded: if they have pre-existing diarrhea/illness, or if they have a co-morbid disease or condition that would preclude safe delivery of TheraSphere® treatment and place the patient at undue risk. Required Lab Parameters AST or ALT \<5 times ULN For HCC: Bilirubin ≤ 2.0 mg/dl (unless segmental infusion is used) Negative pregnancy test in premenopausal women For other primary or secondary liver neoplasia, bilirubin levels specific to the primary or secondary liver neoplasia will be determined to confirm suitability for TheraSphere® treatment Negative pregnancy test in premenopausal women Endpoints Provide TheraSphere® for patients who it is determined by their treating physicians and/or tumor board that the device is appropriate for the treatment of unresectable HCC in accordance with the FDA recommendation of use of a HUD within its approved indication or for the treatment of the patient's other primary or secondary liver neoplasia and is in accordance with the FDA recommendation of use of a HUD outside of its approved indication. Evaluate SAE's associated with TheraSphere® treatment. TheraSphere® Treatment: Suggested Table of Time and Events. TIME Pre-Treatment Evaluation First Treatment First Follow-up Visit Second Treatment3 Post-Treatment Follow-up3 EVENTS -30 to -5 Days Day 0 Day 21 - 42 Day 30 - 90 3 months * 24 months
Primary Outcome
life saving measure\_ days of survival after the treament
Conditions Studied
Interventions
- DEVICE TheraSphere
Study Locations (1)
Texas
- The Liver Institute at Methodist Dallas Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2014-05-22 |
| Est. Completion | 2021-04-16 |
| Phase | NA |
What the finished NCT04090645 record still lists
NCT04090645 is an interventional study that assigns participants to a tested intervention. The registered 187 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Liver, Cancer of, Non-Resectable appearing as the primary indexed condition, and to 1 intervention - of which TheraSphere is the first listed.
NCT04090645 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04090645 about?
NCT04090645 is a clinical study titled "TheraSphere & Treatment of Unresectable Primary or Unresectable Secondary Liver Cancer". Protocol Synopsis Title A Humanitarian Device Exemption Use Protocol of TheraSphere® For Treatment of Unresectable Primary or Secondary Liver Neoplasia Supplier BTG International Canada Inc. Type of Clinical Use Post-Marketing: TheraSphere® commercially distributed under HDE # 980006 Objectives •...
What is the current status of trial NCT04090645?
This trial is currently completed. It is a NA study. The enrollment target is 187 participants. The study started on 2014-05-22. Estimated completion is 2021-04-16.
What conditions does trial NCT04090645 study?
This clinical trial studies the following conditions: Liver, Cancer of, Non-Resectable.
What interventions are being tested in trial NCT04090645?
The interventions under investigation include: TheraSphere (DEVICE).
Who is sponsoring clinical trial NCT04090645?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04090645 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04090645's enrollment target sits among peer trials
187 579th of 2000 higher than 1,422 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06153251 · 187 participants · Phase 1
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- NCT06254898 · 187 participants · NA
Use of Incentives for Stressful Medical Procedures
- NCT07062237 · 187 participants · NA
A Randomized Clinical Trial Comparing Embryo Euploidy Rates Following Ultrashort Versus Standard Abstinence
- NCT07217574 · 187 participants
Program in Oncology for Tribal Health Systems.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI